Patents-Review.com
🔗 Permalink
Assignee profile:

CENTAURUS BIOPHARMA CO., LTD.

City:

Beijing

Country:

China

Published Applications:

29

Last publication date:

2021-09-09

Patent Grants:

28

Last grant date:

2024-09-24

Top Inventors for applications by CENTAURUS BIOPHARMA CO., LTD.

These are the the leading inventors for applications assigned to CENTAURUS BIOPHARMA CO., LTD.:

Recent patent applications by CENTAURUS BIOPHARMA CO., LTD.

CENTAURUS BIOPHARMA CO., LTD. based in Beijing, CN has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2021-09-09 ✅ Patent 12,097,204 granted on 2024-09-24
US20210275534A1
Human necessities

Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

 #2 | 2021-08-12 ✅ Patent 11,773,079 granted on 2023-10-03
US20210246119A1
Chemistry; metallurgy

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine

 #3 | 2021-02-18 ✅ Patent 11,111,240 granted on 2021-09-07
US20210047314A1
Chemistry; metallurgy

Sultam compound and application method thereof

 #4 | 2020-09-17 ✅ Patent 11,098,060 granted on 2021-08-24
US20200291042A1
Chemistry; metallurgy

Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof

 #5 | 2020-09-17 ✅ Patent 11,254,665 granted on 2022-02-22
US20200291012A1
Chemistry; metallurgy

Crystalline sulfamide compound

 #6 | 2019-11-21 ✅ Patent 10,829,492 granted on 2020-11-10
US20190352306A1
Chemistry; metallurgy

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

 #7 | 2019-11-21 ✅ Patent 11,021,464 granted on 2021-06-01
US20190352281A1
Chemistry; metallurgy

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt

 #8 | 2019-10-03 ✅ Patent 10,570,141 granted on 2020-02-25
US20190300533A1
Chemistry; metallurgy

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof

 #9 | 2019-09-19 ✅ Patent 10,822,319 granted on 2020-11-03
US20190284153A1
Chemistry; metallurgy

Crystal of DPP-IV long-acting inhibitor and salt

 #10 | 2019-07-11 ✅ Patent 10,766,901 granted on 2020-09-08
US20190211021A1
Chemistry; metallurgy

Preparation method for chiral pyrrolopyrimidine compound

 #11 | 2019-06-20 ✅ Patent 10,858,340 granted on 2020-12-08
US20190185453A1
Chemistry; metallurgy

Crystal of salt of quinazoline derivative

 #12 | 2019-06-20 ✅ Patent 10,617,692 granted on 2020-04-14
US20190183899A1
Human necessities

Pyrrolopyrimidine comprising cyclopentyl substituent

 #13 | 2019-06-13 ✅ Patent 10,501,468 granted on 2019-12-10
US20190177335A1
Chemistry; metallurgy

Method for preparing intermediate of 6-arylaminopyridonecarboxamide compound as MEK inhibitor

 #14 | 2019-02-28 ✅ Patent 10,654,826 granted on 2020-05-19
US20190062308A1
Chemistry; metallurgy

1,3,5-triazine derivative and method of using same

 #15 | 2018-08-30 ✅ Patent 10,385,038 granted on 2019-08-20
US20180244649A1
Chemistry; metallurgy

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

 #16 | 2018-08-09 ✅ Patent 10,155,722 granted on 2018-12-18
US20180222853A1
Chemistry; metallurgy

Antitumor compound targeting IDH2 mutation and method of use thereof

 #17 | 2018-07-26 ✅ Patent 10,329,277 granted on 2019-06-25
US20180208581A1
Chemistry; metallurgy

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity

 #18 | 2018-04-26 ✅ Patent 10,155,775 granted on 2018-12-18
US20180111950A1
Chemistry; metallurgy

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

 #19 | 2018-03-29 ✅ Patent 10,231,973 granted on 2019-03-19
US20180085369A1
Human necessities

Salts of quinazoline derivative and method for preparing the same

 #20 | 2017-05-25 ✅ Patent 10,112,922 granted on 2018-10-30
US20170144986A1
Chemistry; metallurgy

Inhibitor of bruton's tyrosine kinase

 #21 | 2016-07-28 ✅ Patent 9,725,439 granted on 2017-08-08
US20160214964A1
Chemistry; metallurgy

Quinazoline derivative and preparation method therefor

 #22 | 2016-01-07 ✅ Patent 9,708,295 granted on 2017-07-18
US20160002205A1
Chemistry; metallurgy

Substituted 2-aminopyridine protein kinase inhibitor

 #23 | 2015-10-22 ✅ Patent 9,926,299 granted on 2018-03-27
US20150299171A1
Chemistry; metallurgy

Inhibitors of bruton's tyrosine kinase

 #24 | 2015-01-15 ✅ Patent 9,309,211 granted on 2016-04-12
US20150018341A1
Chemistry; metallurgy

Arylalkene derivatives and use thereof as selective estrogen receptor modulators

 #25 | 2014-10-02 ✅ Patent 9,550,781 granted on 2017-01-24
US20140296261A1
Chemistry; metallurgy

Kinase modulating compounds, compositions containing the same and use thereof

 #26 | 2014-03-20 ✅ Patent 9,540,396 granted on 2017-01-10
US20140080804A1
Chemistry; metallurgy

6-arylamino pyridone carboxamide as MEK inhibitors

 #27 | 2014-01-16
US20140018380A1
Chemistry; metallurgy

BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS

 #28 | 2013-10-24 ✅ Patent 9,428,508 granted on 2016-08-30
US20130281438A1
Chemistry; metallurgy

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

 #29 | 2010-09-02 ✅ Patent 8,772,312 granted on 2014-07-08
US20100222270A1
Chemistry; metallurgy

Heterocyclic compounds as CRTH2 receptor antagonists

Also check out CENTAURUS BIOPHARMA CO., LTD.'s (Beijing, China) applicant profile with 29 patent applications submitted.

AssigneeID:

43434 ⎘